



Office de la Propriété
Intellectuelle
du Canada

Un organisme
d'Industrie Canada

Canadian
Intellectual Property
Office

An agency of
Industry Canada

CA 2318432 C 2003/01/28

(11)(21) **2 318 432**

(12) **BREVET CANADIEN
CANADIAN PATENT**

(13) **C**

(86) Date de dépôt PCT/PCT Filing Date: 1999/03/26

(87) Date publication PCT/PCT Publication Date: 1999/10/07

(45) Date de délivrance/Issue Date: 2003/01/28

(85) Entrée phase nationale/National Entry: 2000/09/26

(86) N° demande PCT/PCT Application No.: US 1999/006445

(87) N° publication PCT/PCT Publication No.: 1999/049885

(30) Priorités/Priorities: 1998/03/27 (60/079,783) US;
1998/10/29 (60/106,170) US

(51) Cl.Int.⁶/Int.Cl.⁶ A61K 38/39, C07K 14/78

(72) Inventeurs/Inventors:

HUDSON, BILLY G., US;
SARRAS, MICHAEL P., JR., US

(73) Propriétaire/Owner:

UNIVERSITY OF KANSAS MEDICAL CENTER, US

(74) Agent: SMART & BIGGAR

(54) Titre : UTILISATION DE DOMAINES ISOLES DE COLLAGENE DU TYPE IV POUR MODIFIER DES
INTERACTIONS CELLULAIRES ET TISSULAIRES

(54) Title: THE USE OF ISOLATED DOMAINS OF TYPE IV COLLAGEN TO MODIFY CELL AND TISSUE
INTERACTIONS

(57) **Abrégé/Abstract:**

The instant invention provides methods and kits for inhibiting angiogenesis, tumor growth and metastasis, and endothelial cell interactions with the extracellular matrix, involving contacting the tumor or animal tissue with at least one isolated type IV collagen NC1 α chain nonomer. In a specific embodiment of the invention, the isolated domain of type IV collagen comprises the NC1 (α 1), (α 2), (α 3), or (α 6) chain monomer, or protein constructs having substantially the same structure as the NC1 (α 1), (α 2), (α 3), or (α 6) chain monomer.

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 38/39 // C07K 14/78	A2	(11) International Publication Number: WO 99/49885 (43) International Publication Date: 7 October 1999 (07.10.99)
(21) International Application Number: PCT/US99/06445 (22) International Filing Date: 26 March 1999 (26.03.99) (30) Priority Data: 60/079,783 27 March 1998 (27.03.98) US 60/106,170 29 October 1998 (29.10.98) US (71) Applicant: UNIVERSITY OF KANSAS MEDICAL CENTER [US/US]; 3901 Rainbow Boulevard, Kansas City, KS 66160 (US). (72) Inventors: HUDSON, Billy, G.; Box 420, Omaha Park, AR 72662 (US). SARRAS, Michael, P., Jr.; 10820 Countryside Drive, Kansas City, KS 66103 (US). (74) Agent: HARPER, David, S.; McDonnell Boehnen Hulbert & Berghoff, 300 South Wacker Drive, Chicago, IL 60606 (US).		(81) Designated States: AU, CA, JP, MX, European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published <i>Without international search report and to be republished upon receipt of that report.</i>
(54) Title: THE USE OF ISOLATED DOMAINS OF TYPE IV COLLAGEN TO MODIFY CELL AND TISSUE INTERACTIONS (57) Abstract The instant invention provides methods and kits for inhibiting angiogenesis, tumor growth and metastasis, and endothelial cell interactions with the extracellular matrix, involving contacting the tumor or animal tissue with at least one isolated type IV collagen NC1 α chain monomer. In a specific embodiment of the invention, the isolated domain of type IV collagen comprises the NC1 (α1), (α2), (α3), or (α6) chain monomer, or protein constructs having substantially the same structure as the NC1 (α1), (α2), (α3), or (α6) chain monomer.		

76909-152 (S)

THE USE OF ISOLATED DOMAINS OF TYPE IV COLLAGEN TO MODIFY CELL
AND TISSUE INTERACTIONS

Field of the Invention

This invention relates to methods and kits for
5 inhibiting angiogenesis, tumor growth and metastasis, and
endothelial cell interactions with the extracellular matrix.

Background of the Invention

Angiogenesis, the process of formation of new blood
vessels, plays an important role in physiological processes
10 such as embryonic and postnatal development as well as in wound
repair. Formation of blood vessels can also be induced by
pathological processes involving inflammation (e.g., diabetic
retinopathy and arthritis) or neoplasia (e.g., cancer)
(Folkman, 1985, Perspect, Biol. Med., 29, 10).
15 Neovascularization is regulated by angiogenic growth factors
secreted by tumor or normal cells as well as the composition of
the extracellular matrix and by the activity of endothelial
enzymes (Nicosia and Ottinetti, 1990, Lab. Invest., 63, 115).

During the initial stages of angiogenesis, endothelial cell sprouts appear through gaps in the basement membrane of pre-existing blood vessels (Nicosia and Ottinetti, 1990, *supra*; Schoefl, 1963, Virehous Arch, Pathol. Anat. 337, 97-141; Ausprunk and Folkman, 1977, Microvasc. Res. 14, 53-65; Paku and Paweletz, 1991, Lab. Invest. 63, 334-346). As
5 new vessels form, their basement membrane undergoes complex structural and compositional changes that are believed to affect the angiogenic response (Nicosia, et. al., 1994, Exp. Biology, 164, 197-206). Early planar culture models have shown that basement membrane molecules modulate the attachment, migration and proliferation and organizational behavior of endothelial cells (Nicosia, et. al., 1994, *supra*). More recent
10 studies with three-dimensional aortic culture models that more closely simulate angiogenic conditions during wound healing in vivo suggest that basement membrane is a dynamic regulator of angiogenesis whose function varies according to its molecular components (Nicosia, 1994, *supra*).

A common feature of all solid tumor growth is the requirement for a blood supply.
15 Therefore, numerous laboratories have focused on developing anti-angiogenic compounds based on growth factors and their receptors. While this approach has led to some success, the number of growth factors known to play a role an angiogenesis is large. Therefore, the possibility exists that growth factor antagonists may have only limited use in treating cancer since tumors and associated inflammatory cells likely produce a wide variety of
20 factors that can induce angiogenesis.

In this regard, a strategy that targets a common feature of angiogenesis, such as endothelial cell adhesion to the extracellular matrix (ECM), might be expected to have a profound physiological impact on tumor growth in humans. This notion is supported by the fact that antagonists of specific ECM cell adhesion receptors such as $\alpha v\beta 3$ and $\alpha v\beta 5$

integrins can block angiogenesis. Furthermore, the $\alpha v\beta 3$ integrin is expressed most prominently on cytokine -activated endothelial and smooth muscle cells and has been shown to be required for angiogenesis. (Varner et al., Cell Adhesion and Communication 3:367-374 (1995); Brooks et al., Science 264:569-571 (1994)). Based on these findings, a
5 potentially powerful new approach to anti-angiogenic therapy might be to specifically target critical regulatory domains within distinct ECM components.

The basement membrane (basal lamina) is a sheet-like extracellular matrix (ECM), which is a basic component of all tissues. The basal lamina provides for the compartmentalization of tissues, and acts as a filter for substances traveling between tissue
10 compartments. Typically the basal lamina is found closely associated with an epithelium or endothelium in all tissues of an animal including blood vessels and capillaries. The basal lamina components are secreted by cells and then self assemble to form an intricate extra-cellular network. The formation of biologically active basal lamina is important to the development and differentiation of the associated cells.

15 Type IV collagen has been shown to be a major structural component of basement membranes. The protomeric form of type IV collagen is formed as a heterotrimer made up from a number of different subunit chains called $\alpha 1(IV)$ through $\alpha 6(IV)$. Up to now, six genetically distinct α -chains belonging to two classes with extensive homology have been identified, and their relative abundance has been demonstrated to be tissue specific.
20 The type IV collagen heterotrimer is characterized by three distinct structural domains: the non-collagenous (NC1) domain at the carboxyl terminus; the triple helical collagenous domain in the middle region; and the 7S collagenous domain at the amino terminus. (Martin, et. al., 1988, Adv. Protein Chem. 39:1-50; Gunwar, et. al. 1991, J. Biol. Chem. 266:14088-14094).

76909-152(S)

The capability of expression of recombinant α (IV) NC1 domains provides the opportunity to study the effect of specific domains on many biological processes, such as angiogenesis, tumor metastasis, cell binding to basement
5 membranes, and assembly of Type IV collagen molecules.

Summary of the Invention

The instant invention provides methods and kits for inhibiting angiogenesis, tumor growth and metastasis, and endothelial cell interaction with the extracellular matrix,
10 each method comprising contacting the tumor or animal tissue with one or more isolated type IV collagen NC1 α chain monomer selected from the group consisting of α 1, α 2, α 3, and α 6 NC1 chain monomers.

According to one aspect of the present invention,
15 there is provided an in vitro method for inhibiting angiogenesis in an animal tumor or tissue comprising contacting the tumor or animal tissue with an amount effective to inhibit angiogenesis of a polypeptide comprising one or more recombinant NC1 α chain monomers of type IV collagen selected
20 from the group consisting of α 1, α 2, α 3, and α 6 NC1 chain monomers.

According to another aspect of the present invention, there is provided an in vitro method for inhibiting endothelial cell interaction with the extracellular matrix in an animal
25 tumor or tissue comprising contacting the tumor or animal tissue with an amount effective to inhibit endothelial cell interaction with the extracellular matrix of a polypeptide comprising one or more recombinant NC1 α chain monomers of type

76909-152 (S)

IV collagen selected from the group consisting of $\alpha 1$, $\alpha 2$, $\alpha 3$, and $\alpha 6$ NC1 chain monomers.

According to still another aspect of the present invention, there is provided a pharmaceutical composition comprising: (a) a recombinant type IV collagen NC1 $\alpha 1$ chain monomer; and (b) a pharmaceutically acceptable carrier.

According to yet another aspect of the present invention, there is provided a pharmaceutical composition comprising: (a) a recombinant type IV collagen NC1 $\alpha 2$ chain monomer; and (b) a pharmaceutically acceptable carrier.

According to a further aspect of the present invention, there is provided a pharmaceutical composition comprising: (a) a recombinant type IV collagen NC1 $\alpha 3$ chain monomer; and (b) a pharmaceutically acceptable carrier.

According to still a further aspect of the present invention, there is provided a pharmaceutical composition comprising: (a) type IV collagen NC1 $\alpha 3$ chain monomer at a dosage of between 0.01 $\mu\text{g/kg}$ body weight and 10 mg/kg body weight; and (b) a pharmaceutically acceptable carrier.

According to yet a further aspect of the present invention, there is provided the use of a pharmaceutical composition as described herein for inhibiting tumor growth or metastasis or for treating an angiogenesis-mediated disease or condition in a mammal.

According to still a further aspect of the present invention, there is provided a commercial package comprising an effective amount of a pharmaceutical composition as described herein, together with instructions for the use thereof for inhibiting tumor growth or metastasis or for

76909-152 (S)

treating an angiogenesis-mediated disease or condition in a mammal.

According to another aspect, the invention provides an in vitro method for inhibiting angiogenesis in
5 an animal tumor or tissue comprising contacting the tumor or animal tissue with an amount effective to inhibit angiogenesis of one or more NC1 α chain monomers of type IV collagen selected from the group consisting of $\alpha 1$, $\alpha 2$, $\alpha 3$ and $\alpha 6$ NC1 chain monomers wherein the $\alpha 2$ monomer does not
10 occur in combination with the $\alpha 1$ monomer.

According to another aspect, the invention provides an in vitro method for inhibiting endothelial cell interaction with the extracellular matrix in an animal tumor or animal tissue comprising contacting the tumor or animal
15 tissue with an amount effective to inhibit endothelial cell interaction with the extracellular matrix of one or more NC1 α chain monomers of type IV collagen selected from the group consisting of $\alpha 1$, $\alpha 2$, $\alpha 3$, and $\alpha 6$ NC1 chain monomers wherein the $\alpha 2$ monomer does not occur in combination with the $\alpha 1$
20 monomer.

According to another aspect, the invention provides a pharmaceutical composition comprising: (a) type IV collagen NC1 $\alpha 3$ chain monomer in an amount effective to inhibit angiogenesis or tumor metastasis; and (b) a
25 pharmaceutically acceptable carrier.

Brief Description of the Drawings

Figure 1 illustrates the effects of NC1 (Hexamer) and 7S domains of Type IV collagen at a 50 $\mu\text{g/ml}$

76909-152(S)

concentration on angiogenesis from mouse thoracic aorta organ cultures.

Figure 2 illustrates the effects of 7S domain of Type IV collagen on angiogenesis from mouse thoracic aorta organ cultures. The domain concentrations employed in this experiment were 0 $\mu\text{g/ml}$ (control); 0.5 $\mu\text{g/ml}$; 5 $\mu\text{g/ml}$ and 50 $\mu\text{g/ml}$.

Figure 3 illustrates the effects of NC1 (Hexamer) domain of Type IV collagen on angiogenesis from mouse thoracic aorta organ cultures. The domain concentrations employed in this experiment were 0 $\mu\text{g/ml}$ (control); 0.5 $\mu\text{g/ml}$ and 5 $\mu\text{g/ml}$ and 50 $\mu\text{g/ml}$.

Figure 4 are photographs of mouse thoracic aorta segments embedded in Matrigel™ (EHS basement membrane matrix, Collaborative Biomedical Products, Bedford, MA) at 5 days of culture. Control specimen (0 $\mu\text{g/ml}$ of NC1 (Hexamer) and 7S domains) exhibited

growth of microvessels from the cultured tissue into the matrix (Figure 4A). In contrast, angiogenesis was inhibited in specimens cultured with 50 $\mu\text{g/ml}$ of 7S domain (Figure 4B) and NC1 (Hexamer) domain (Figure 4C).

Figure 5 is a graphical representation of data demonstrating the in vivo effect of IV
5 injection of recombinant ($\alpha 1$) type IV collagen monomer on angiogenesis using fibrin implants in rats.

Figure 6 is a graphical representation of data demonstrating that the recombinant ($\alpha 1$) and ($\alpha 2$) NC1 monomers inhibit the bFGF-induced increase in angiogenic index in vivo.

Figure 7 is a graphical representation of demonstrating the dose response effect of
10 recombinant ($\alpha 2$) NC1 monomer on the bFGF-induced increase in total blood vessel branch points in vivo.

Figure 8 is a graphical representation of data demonstrating the dose response effect of recombinant ($\alpha 2$) NC1 monomer on the bFGF-induced increase in angiogenic index in vivo.

15 **Figure 9** is a graphical representation of data demonstrating the dose response effect of recombinant ($\alpha 2$) NC1 monomer on the bFGF-induced increase in angiogenic index in vivo.

Figure 10 is a graphical representation of data demonstrating the effect of recombinant ($\alpha 1$) and ($\alpha 2$) NC1 monomers on mean CS-1 melanoma tumor weight in vivo.

20 **Figure 11** is a graphical representation of data demonstrating the dose response effect of recombinant ($\alpha 2$) NC1 monomer on mean CS-1 melanoma tumor weight in vivo.

Figure 12 is a graphical representation of data demonstrating the effect of recombinant ($\alpha 1$), ($\alpha 2$), and ($\alpha 4$) NC1 monomers on mean HT1080 tumor weight in vivo.

WO 99/49885

PCT/US99/06445

Figure 13 is a graphical representation of data demonstrating the effect of recombinant ($\alpha 1$), ($\alpha 2$), ($\alpha 3$) and ($\alpha 5$) NC1 monomers on mean HEP-3 tumor weight in vivo.

Figure 14 is a graphical representation of data demonstrating human endothelial cell adhesion to immobilized NC1 α monomers.

5 **Figure 15** is a graphical representation of data demonstrating the effect of soluble $\alpha 1$ and $\alpha 2$ NC1 monomers on human endothelial cell adhesion to pepsinized collagen type IV.

Figure 16 is a graphical representation of data demonstrating the effect of isolated recombinant NC1 monomers on human endothelial cell migration in vitro.

Figure 17 A-F provides the sequences of each type IV collagen α chain monomer.

10

Description of the Preferred Embodiments

Within this application, unless otherwise stated, the techniques utilized may be found in any of several well-known references such as: *Molecular Cloning: A Laboratory Manual* (Sambrook, et al., 1989, Cold Spring Harbor Laboratory Press), *Gene Expression Technology* (Methods in Enzymology, Vol. 185, edited by D. Goeddel, 1991. Academic Press, San Diego, CA), "Guide to Protein Purification" in *Methods in Enzymology* (M.P. Deutshcer, ed., (1990) Academic Press, Inc.); *PCR Protocols: A Guide to Methods and Applications* (Innis, et al. 1990. Academic Press, San Diego, CA), *Culture of Animal Cells: A Manual of Basic Technique, 2nd Ed.* (R.I. Freshney. 1987. Liss, Inc. New York, NY), and *Gene Transfer and Expression Protocols*, pp. 109-128, ed. E.J. Murray, The Humana Press Inc., Clifton, N.J.).

15
20

As used herein, the term Type IV collagen domain encompasses the group of molecules including the non-collagenous NC1 domain (Hexamer) and 7S collagenous domains, as well as NC1 α chain monomers.

The invention comprises methods for using Type IV collagen NC1 α -monomers (ie: $\alpha 1$, $\alpha 2$, $\alpha 3$, and $\alpha 6$), which are defined to include such monomers isolated from any multicellular organism or produced via recombinant protein expression from a gene encoding such a monomer from any multicellular organism, and also to encompass various
5 modifications, additions, and/or deletions to such monomers.

In one aspect, the present invention provides methods and kits for inhibiting angiogenesis in an animal tissue comprising contacting the tumor or animal tissue with an amount effective to inhibit angiogenesis of a polypeptide composition comprising one or more isolated type IV collagen NC1 α chain monomer selected from the group consisting of
10 $\alpha 1$, $\alpha 2$, $\alpha 3$, and $\alpha 6$ NC1 chain monomers.

In another aspect, the present invention provides methods and kits for inhibiting tumor growth in tissue comprising contacting the tumor or tissue with an amount effective to inhibit tumor growth of a polypeptide composition comprising one or more isolated type IV collagen NC1 α chain monomer selected from the group consisting of $\alpha 1$, $\alpha 2$, $\alpha 3$, and
15 $\alpha 6$ NC1 chain monomers.

In another aspect, the present invention provides methods and kits for inhibiting tumor metastasis in tissue comprising contacting the tumor or tissue with an amount effective to inhibit metastasis of a polypeptide composition comprising one or more isolated type IV collagen NC1 α chain monomer selected from the group consisting of $\alpha 1$, $\alpha 2$, $\alpha 3$,
20 and $\alpha 6$ NC1 chain monomers.

In a further aspect, the present invention provides methods and kits for inhibiting endothelial cell interactions with the extracellular matrix in tissue comprising contacting the tumor or tissue with an amount effective to inhibit endothelial cell interactions with the

extracellular matrix of a polypeptide composition comprising one or more isolated type IV collagen NC1 α chain monomer selected from the group consisting of $\alpha 1$, $\alpha 2$, $\alpha 3$, and $\alpha 6$ NC1 chain monomers.

The NC1-encoding domain of each of the six α chain cDNAs has been cloned into
5 a vector for recombinant protein expression as previously described (Sado et al., *Kidney Intl.* 53:664-671 (1998). The vectors are
used to stably transfect human kidney 293 cells, which produce the recombinant protein. The DNA and deduced amino acid sequences of the recombinant type IV collagen alpha chain monomers produced as described are shown in Figure 17A-F. The first 17 amino
10 acids corresponds to a BM40 signal sequence (which is cleaved from the mature protein), to facilitate protein secretion. All the secreted proteins (ie: mature proteins) start with the sequence APLA followed by the affinity tag, DYKDDDDK at the amino terminus. This tag facilitates purification and identification of the material, and does not interfere with biological activity of the recombinant NC1 α chain monomer.

15 The type IV collagen NC1 α chain monomers can be produced by any method known in the art, including using recombinant DNA technology or biochemical peptide synthesis technology, or by isolating the NC1 domains from animal sources, such as from basement membrane sources such as bovine lens capsule and bovine kidney glomeruli. (Peczon et al., *Exp. Eye Res.* 30:155-165 (1980); Langeveld et al., *J. Biol. Chem.*
20 263:10481-10488 (1988); Gunwar et al., *J. Biol. Chem.* 266:14088-14094 (1991))

In practicing the invention, the amount or dosage range of type IV collagen NC1 α chain monomers employed is one that effectively inhibits angiogenesis, tumor growth, tumor metastasis, and/or endothelial cell-extracellular matrix interactions. An inhibiting

WO 99/49885

PCT/US99/06445

amount of NC1 α chain monomers that can be employed ranges generally between about 0.01 $\mu\text{g/kg}$ body weight and about 10 mg/kg body weight, preferably ranging between about 0.05 $\mu\text{g/kg}$ and about 5 mg/kg body weight.

The NC1 α chain monomers may be administered by any suitable route, including orally, parentally, by inhalation spray, rectally, or topically in dosage unit formulations containing conventional pharmaceutically acceptable carriers, adjuvants, and vehicles. The term parenteral as used herein includes, subcutaneous, intravenous, intraarterial, intramuscular, intrasternal, intratendinous, intraspinal, intracranial, intrathoracic, infusion techniques or intraperitoneally. In preferred embodiments, the NC1 α chain monomers are administered intravenously or subcutaneously.

The NC1 α chain monomers may be made up in a solid form (including granules, powders or suppositories) or in a liquid form (*e.g.*, solutions, suspensions, or emulsions). The NC1 α chain monomers of the invention may be applied in a variety of solutions. Suitable solutions for use in accordance with the invention are sterile, dissolve sufficient amounts of the NC1 α chain monomers, and are not harmful for the proposed application.

The NC1 α chain monomers may be subjected to conventional pharmaceutical operations such as sterilization and/or may contain conventional adjuvants, such as preservatives, stabilizers, wetting agents, emulsifiers, buffers etc.

For administration, the NC1 α chain monomers are ordinarily combined with one or more adjuvants appropriate for the indicated route of administration. The compounds may be admixed with lactose, sucrose, starch powder, cellulose esters of alkanolic acids, stearic acid, talc, magnesium stearate, magnesium oxide, sodium and calcium salts of phosphoric and sulphuric acids, acacia, gelatin, sodium alginate, polyvinylpyrrolidone,

WO 99/49885

PCT/US99/06445

and/or polyvinyl alcohol, and tableted or encapsulated for conventional administration. Alternatively, the compounds of this invention may be dissolved in saline, water, polyethylene glycol, propylene glycol, carboxymethyl cellulose colloidal solutions, ethanol, corn oil, peanut oil, cottonseed oil, sesame oil, tragacanth gum, and/or various
5 buffers. Other adjuvants and modes of administration are well known in the pharmaceutical art. The carrier or diluent may include time delay material, such as glyceryl monostearate or glyceryl distearate alone or with a wax, or other materials well known in the art.

The present invention may be better understood with reference to the
10 accompanying examples that are intended for purposes of illustration only and should not be construed to limit the scope of the invention, as defined by the claims appended hereto.

Example 1 – In Vitro Effect on Angiogenesis

With modifications, the procedures of Nicosia and Ottinetti (1990), *supra*, and
15 Nicosia, et. al. (1994), *supra*, were utilized for experiments designed to test the effect of Type IV collagen on angiogenesis under *in vitro* conditions. The model has been used to study the effects of growth factors and extracellular matrix molecules on the angiogenic response and employs aortic rings cultures in three-dimensional collagen gels under serum-free conditions. These experiments are outlined below.

A. Methods

Experiments were performed with 1-3 month old Swiss Webster male mice. Following anesthesia, the thoracic aorta was excised under aseptic conditions and transferred to sterile MCDB 131 sterile growth medium (Clonetics, San Diego, CA) containing antibiotics. Fat was dissected away from the aorta and approximately six to

76909-152 (S)

eight 1 mm thoracic segments were obtained from each specimen. Segments were transferred to 48 well tissue culture plates. The wells of these plates were layered with 100 microliters of Matrigel™ (EHS basement membrane, Collaborative Biomedical Products, Bedford, MA) prior to transfer of the aortic segments. The Matrigel™ was diluted 5 1:1 with MCDB 131 growth medium prior to use. The segments were centered in the wells and an additional 100 microliters of Matrigel™ was then placed over the specimens. The aortic segments were therefore embedded in the basement membrane matrix. Each well then received 300 microliters of MCDB 131 growth medium. The plates were placed in an incubator maintained at 37° C with 5% CO₂. Specimens were observed daily over a 10 7 day period. Newly growing microvessels were counted using an inverted phase microscope at various times during the culture period, but data is expressed at 3 and 5 days of culture. To test for the effect of Type IV collagen on angiogenesis, domains at known concentrations were mixed with the Matrigel™ and with the MCDB 131 growth medium. Fresh MCDB 131 growth medium (plus and minus collagen domains) was changed every 15 3 days.

B. Results

After establishing the time course of angiogenesis under control conditions (Matrigel™ plus MCDB 131 growth medium), experiments were performed using various 20 concentrations of Type IV collagen (isolated from bovine lens) NC1 (hexamer) and 7S domains. Data represents the analysis of at least 3 specimens per experimental condition. In the first experiment (Figure 1), analysis indicated that at a concentration of 50 µg/ml, NC1 domain and 7S domain significantly inhibited angiogenesis as monitored at 3 and 5 days of culture. In the second experiment, various concentrations of these domains were

analyzed. As indicated in Figure 3, 7S domain at 50 $\mu\text{g/ml}$ again significantly inhibited angiogenesis at 3 and 5 days. Inhibition was reduced at 5 and 0.5 $\mu\text{g/ml}$ concentrations. As indicated in Figure 2, NC1 domain was less effective in blocking angiogenesis as compared to that observed in the first experiment (Figure 1), although it was still effective. In addition, as compared to the 7S domain, there was less of a correlation between concentration and inhibitory action.

Figure 4A-C are photographs of mouse thoracic aorta segments embedded in MatrigelTM (EHS basement membrane matrix, Collaborative Biomedical Products, Bedford, MA) at 5 days of culture in the presence or absence of 50 $\mu\text{g/ml}$ of Type IV collagen domains. The control specimen (no domains) exhibited growth of microvessels from the cultured tissue into the matrix (Figure 4A). In contrast, angiogenesis inhibition was observed in tissues cultured in the presence of 50 $\mu\text{g/ml}$ of 7S (Figure 4B) and NC1 (Hexamer) domain (Figure 4C).

Example 2. Subcutaneous fibrin implant angiogenesis

Recombinant human type IV collagen NC1 ($\alpha 3$) monomer (Sado et al., Kidney International 53:664-671 (1998)) was injected intravenously in Fisher 344 rats containing fibrin implants surgically placed subcutaneously, a modified version of the method described by Dvorak et al (Lab. Invest. 57(6):673-686 (1987)). The implants were then removed and directly analyzed using an inverted microscope. The analysis involved counting the number of blood vessels that had grown into the fibrin in the control and experimental group.

Briefly, 4 fibrin implants were surgically implanted subcutaneously into Fisher 344 rats (2 dorsal and 2 ventral sides). The average rat weight was approximately 125 grams.

WO 99/49885

PCT/US99/06445

Three rats (EXP) were given tail vein injections of either control (fibrin alone), 100 μ l of 100 μ g/ml of 7S domain of type IV collagen (approximately 0.80 mg/kg body weight), 100 μ l of 100 μ g/ml of type IV collagen hexamer (approximately 0.80 mg/kg body weight), or recombinant collagen type IV NC1 (α 3) monomer at a concentration of 1.26 mg/ml in PBS (120 μ g protein, or approximately 0.96 mg/kg body weight) and 3 rats (C) were given 100 μ l tail vein injections of PBS. Injections of recombinant protein were given every other day for five doses. The injection schedule was as follows:

Day 1: (implant day) injection and remove blood sample (EXP and C)
 Day 3: Injection (EXP and C)
 Day 5: Injection and remove blood sample (EXP and C)
 Day 7: Injection (EXP and C)
 Day 9: Injection and remove blood sample (EXP and C)
 Day 11: Remove and fix implants (save blood sample) (EXP and C)

The results of one experiment were as follows:

2 week in vivo experiment:

Control (fibrin alone)	about 66 BV
7S domain of type IV lens collagen (100 μ g/ml)	None
Hexamer of type IV lens collagen (100 μ g/ml)	None
Monomer (α 3)	None

The results are shown as the mean number of blood vessels per implant. The results of this study demonstrate that isolated domains of type IV collagen, including the α 3 monomer, can significantly inhibit capillary growth in the in vivo fibrin clot implant model. In subsequent experiments, the inhibitory effect was occasionally seen to attenuate with time, suggesting that higher dosages or more frequent injections might be even more effective.

A similar experiment was conducted using recombinant human type IV collagen NC1 (α 1) monomer (100 μ l of a 1 μ g/ μ l solution; approximately 0.80 mg/kg body weight)

and comparing the number of blood vessels that had grown into the fibrin at day 11 of treatment relative to the control group. Three rats per group were analyzed with each rat having 4 implants. These experiments demonstrated that administration of the $\alpha 1$ monomer significantly inhibited capillary growth in the in vivo fibrin clot implant model
5 (Figure 5).

Example 3. Recombinant NC1 ($\alpha 2$) domain inhibits angiogenesis in vivo

We next tested the effects of systemic administration of soluble NC1 α -chain
10 monomers in the chick embryo CAM angiogenesis assay.

Angiogenesis was induced in the CAMs of 10 day old chick embryos with bFGF as described (Brooks et al., Cell 92:391-400 (1998)). Twenty four hours later the embryos were systemically treated with various concentrations of recombinant NC1 α -chain monomers, in a total volume of 100 μ l of sterile phosphate buffered saline (PBS). Two
15 days later the embryos were sacrificed and the filter discs and CAM tissues removed. Angiogenesis was quantitated by counting the number of angiogenic blood vessel branch points in the confined area of the filter disc. The Angiogenic Index is defined as the number of branch points from experimental treatment minus control treatment.

In initial experiments, recombinant $\alpha 1$ or $\alpha 2$ NC1 domains were injected at a
20 concentration of 50 μ g per embryo. At this concentration, the NC1 domains were shown to be highly toxic as demonstrated by greater than 90% embryo cell death. However, at lower doses they were well tolerated and showed potent anti-angiogenic activity. A total of 6 individual angiogenesis experiments were conducted with the NC1 domains. However, in two experiments, the bFGF induction was low, making it difficult to interpret

the results. The NC1 α 2 domain appeared to be more consistent and potent than the α 1 NC1 domain at inhibiting angiogenesis. In fact, systemic administration of 30 μ g of NC1 α 2 consistently inhibited angiogenesis by greater than 90% (**Figures 6-9**), as measured by inhibition of the bFGF-induced increase in the angiogenic index and the mean number of blood vessel branch points. In contrast, NC1 α 1 domain showed variable inhibitory activity (0%-50%) throughout the experiments.

Example 4 . Recombinant NC1 domain inhibits melanoma tumor growth in vivo:

Since the growth of all solid tumors depends on angiogenesis to provide nutrients for its continued expansion, reagents that have the capacity to inhibit angiogenesis may significantly inhibit tumor growth. Therefore, we tested the effects of recombinant NC1 domains of type IV collagen for their effects on tumor growth in vivo.

To test the effects of NC1 domains on tumor growth in vivo, we utilized the chick embryo tumor growth assay. Briefly, single cell suspensions of 3 distinct tumor types were applied to the CAM of 10 day old chick embryos. The tumors included CS-1 Melanoma cells (5×10^6), HT1080 human fibrosarcoma cells (4×10^5) and Hep-3 human epidermoid carcinoma cells (2×10^5). The embryos were injected systemically with varying concentrations of NC1 α -chain monomers 24 hours later. The embryos were next allowed to incubate for a total of 7 days, at which time they were sacrificed. The resulting tumors were resected and wet weights determined. A total of 6 tumor growth assays were conducted with the 3 distinct tumor types. A single injection of 10 μ g NC1 α 2 domain inhibited CS1 melanoma tumor growth by approximately 70% relative to control (**Figure 10**). In similar experiments, dose response curves were completed with CS-1 tumors.

Systemic administration of NC1 α 2 resulted in a dose-dependent inhibition of CS-1 melanoma tumor growth in vivo with a maximum inhibition following a single dose at 30 μ g (**Figure 11**). Systemic administration of NC1 α 1 also inhibited CS-1 tumor growth but it was variable and in some experiments failed to inhibit tumor growth (**See Figure 10**).

5 In similar experiments, NC1 α 2 inhibited HT1080 human fibrosarcoma tumor growth by approximately 50% after a single systemic injection of 30 μ g, while NC1 α 1 and α 4 had no effect (**Figure 12**). Finally, systemic administration of NC1 α 2 (30.0 μ g) and α 3 inhibited Hep-3 human epidermoid carcinoma tumor growth by approximately 40% and 60% respectively, and α 1 inhibited Hep-3 tumor growth by approximately 30%, while

10 NC1 α 5 domain failed to inhibit tumor growth (**Figure 13**).

We conclude from these in vivo studies that tumor growth can be inhibited by isolated NC1 α -chain monomers. These molecules can thus be used alone, or to complement the use of existing anti-tumor agents, in providing enhanced and more effective anti-tumor therapy.

15

Example 5. Immobilized NC1 domains support human endothelial cell adhesion

In order for new blood vessels to form, endothelial cells must have the capacity to adhere and migrate through the ECM. Moreover, this endothelial cell-ECM interaction may facilitate signal transduction events required for new blood vessel formation.

20 Therefore, since type IV-collagen is an ECM protein which is known to support cell adhesion, we tested the ability of the NC1 domains to support endothelial cell attachment.

Microtiter plates were coated with 25 μ g/ml of purified NC1 domains followed by incubation with 1% bovine serum albumin (BSA) to block non-specific interactions.

Human endothelial cells (ECV304) were then allowed to attach to the immobilized NC1 domains for 1 hour. Non-adherent cells were removed by washing and attached cells were quantified by measuring the optical density (O.D.) of crystal violet eluted from attached cells. Data bars represent the mean +/- standard error of the O.D. from triplicate wells.

5 Immobilized NC1 $\alpha 2$, $\alpha 3$, and $\alpha 6$ domains supported endothelial cell adhesion while NC1 $\alpha 1$, $\alpha 4$, and $\alpha 5$ domains promoted little if any cell adhesion (**Figure 14**). Soluble NC1 $\alpha 1$ ($\alpha 1$) and $\alpha 2$ ($\alpha 2$) inhibited endothelial cell adhesion to pepsinized collagen type IV by approximately 50% (**Figure 15**).

10 Taken together, these findings demonstrate that isolated, recombinant NC1 domains from the $\alpha 1$, $\alpha 2$, $\alpha 3$, and $\alpha 6$ chains of collagen type IV can mediate human endothelial cell adhesion and/or inhibit endothelial cell adhesion to ECM proteins in vitro, and suggest that the potent anti-angiogenic and anti-tumor activity of the isolated NC1 domains is due to disruption of endothelial cell interaction with the extracellular matrix that are necessary for angiogenesis.

15

Example 6. Endothelial Cell Migration

Invasive cellular processes such as angiogenesis and tumor metastasis also require cellular motility. Thus we evaluated the ability of isolated NC1 domains to support human endothelial cell migration in vitro. These experiments were conducted essentially
20 according to the methods in Brooks et al., J. Clin. Invest. 99:1390-1398 (1997).

The results of these experiments indicate that NC1 $\alpha 2$, $\alpha 3$, and $\alpha 6$ domains can support human endothelial cell migration in vitro, while $\alpha 1$, $\alpha 4$, and $\alpha 5$ domains showed little if any capacity to support endothelial cell migration (**FIG 16**).

Example 7. Efficacy in Lewis lung in vivo tumor

The above studies indicated that specific domains of collagen type IV can promote cell migration in vitro. Thus, we evaluated the ability of NC1 domains to support
5 endothelial cell migration in vivo.

The α (IV) NC1 domain hexamer, isolated by enzymatic digestion of bovine lens capsule basement membrane by known protocols (Peczon et al., Exp. Eye Res. 30:155-165 (1980)) was tested in the metastatic Lewis lung mouse tumor model using a standard protocol which is considered to be a good model of both metastasis and angiogenesis of
10 lung tumors. (See for example, Teicher et al., Anticancer Res. 18:2567-2573 (1998); Guibaud et al., Anticancer Drugs 8:276-282 (1997); Anderson et al., Cancer Res. 56:715-718 (1996)).

Each study consisted of an untreated control group and six treatment groups. There were ten animals per treatment group with 40 mice in the control. In each study, all
15 treatment was administered intravenously once every 2 days for 7 doses starting one day after tumor inoculation. Dosages of α (IV) NC1 hexamer were either 100 μ g/mouse or 200 μ g/mouse. In the Lewis lung study, the tumor cell inoculum was 1×10^6 viable cells. All animals were weighed twice a week throughout the study. Starting one day after the last treatment, 5 mice were periodically sacrificed from each control group to measure
20 pulmonary tumor burden. The experiment was terminated at day 14 when the lungs of the control animals had sufficient tumor mass to provide meaningful evaluation. At that time, the lungs of all remaining animals were excised, weighed, and the number of tumor foci greater than 2 mm in diameter counted. The resulting data showed that both dosages of α (IV) NC1 hexamer significantly reduced the number of visible lung metastases (Mann-

WO 99/49885

PCT/US99/06445

Whitney Rank Sum Test, $p < 0.05$), with 8 visible lung metastases in the control, vs. 5 (100 $\mu\text{g}/\text{mouse}$) and 4 (200 $\mu\text{g}/\text{mouse}$), and the 100 $\mu\text{g}/\text{mouse}$ dosage reduced the lung weights from a median of 520 mg in controls to a median of 462 mg in experimental, while the median lung weight of mice treated with 200 $\mu\text{g}/\text{mouse}$ was 620 mg.

5 Other in vivo studies demonstrated that tumor cell metastasis to the lung can be reduced by 50% or more using intravenous injections of the Type IV collagen domains in murine B16 melanoma, human A375SM melanoma xenografts. Furthermore, injection of the NC1 hexamer also significantly reduced the number of lung tumors in separate Lewis Lung tumor studies.

10

We conclude from all of the above studies that angiogenesis, tumor growth and metastasis, and endothelial cell adhesion to the ECM, can be inhibited by isolated, recombinant domains of type IV collagen. The present invention is thus broadly applicable to a variety of uses which include inhibition of angiogenesis and treatment of
15 diseases and conditions with accompanying undesired angiogenesis, such as solid and blood-borne tumors including but not limited to melanomas, carcinomas, sarcomas, rhabdomyosarcoma, retinoblastoma., Ewing sarcoma, neuroblastoma, osteosarcoma, and leukemia.

The invention is further applicable to treating non-tumorigenic diseases and
20 conditions with accompanying undesired angiogenesis, including but not limited to diabetic retinopathy, rheumatoid arthritis, retinal neovascularization, choroidal neovascularization, macular degeneration., corneal neovascularization, retinopathy of prematurity., corneal graft rejection, neovascular glaucoma., retrolental fibroplasia, epidemic keratoconjunctivitis, Vitamin A deficiency, contact lens overwear, atopic

76909-152 (S)

keratitis, superior limbic keratitis, pterygium keratitis sicca, sogrens, acne rosacea, phylectenulosis, syphilis, Mycobacteria infections, lipid degeneration, chemical burns, bacterial ulcers, fungal ulcers, Herpes simplex infections, Herpes zoster infections, protozoan infections, Kaposi's sarcoma, Mooren ulcer, Terrien's marginal degeneration, 5 marginal keratolysis, traum, systemic lupus, polyarteritis, Wegeners sarcoidosis, scleritis, Steven's Johnson disease, radial keratotomy, sickle cell anemia, sarcoid, pseudoxanthoma elasticum, Pagets disease, vein occlusion, artery occlusion, carotid obstructive disease, chronic uveitis, chronic vitritis, Lyme's disease, Eales disease, Bechets disease, myopia, optic pits, Stargarts disease, pars planitis, chronic retinal detachment, hyperviscosity 10 syndromes, toxoplasmosis, post-laser complications, abnormal proliferation of fibrovascular tissue, hemangiomas, Osler-Weber-Rendu, acquired immune deficiency syndrome, ocular neovascular disease, osteoarthritis, chronic inflammation, Crohn's disease, ulcerative colitis, psoriasis., atherosclerosis, and pemphigoid. See U.S. Patent No. 5,712,291)

15 The invention is also broadly applicable to methods for inhibiting tumor growth and metastasis, reduction of scar tissue formation, reduction of complications due to cell adhesion in organ transplants, and the inhibition of lymphocyte adhesion and mobility.

While the fundamental novel features of the invention have been shown and described, it will be understood that various omissions, substitutions, and changes in the 20 form and details illustrated may be made by those skilled in the art without departing from the spirit of the invention. For example, various modifications, additions. and/or substitutions can be made to the type IV collagen α monomer chains that would be encompassed by the invention. It is the intention, therefore, to be limited only as indicated by the scope of the following claims:

76909-152(S)

CLAIMS:

1. An in vitro method for inhibiting angiogenesis in an animal tumor or tissue comprising contacting the tumor or animal tissue with an amount effective to inhibit angiogenesis of one or more NC1 α chain monomers of type IV collagen selected from the group consisting of $\alpha 1$, $\alpha 2$, $\alpha 3$ and $\alpha 6$ NC1 chain monomers wherein the $\alpha 2$ monomer does not occur in combination with the $\alpha 1$ monomer.
2. An in vitro method for inhibiting endothelial cell interaction with the extracellular matrix in an animal tumor or animal tissue comprising contacting the tumor or animal tissue with an amount effective to inhibit endothelial cell interaction with the extracellular matrix of one or more NC1 α chain monomers of type IV collagen selected from the group consisting of $\alpha 1$, $\alpha 2$, $\alpha 3$, and $\alpha 6$ NC1 chain monomers wherein the $\alpha 2$ monomer does not occur in combination with the $\alpha 1$ monomer.
3. The method of claim 1 or 2, wherein the NC1 α chain monomer is the $\alpha 2$ NC1 chain monomer.
4. The method of claim 1 or 2, wherein the NC1 α chain monomer is the $\alpha 3$ NC1 chain monomer.
5. The method of claim 1 or 2, wherein the NC1 α chain monomer is the $\alpha 6$ NC1 chain monomer.
6. A pharmaceutical composition comprising:
 - (a) type IV collagen NC1 $\alpha 2$ chain monomer; and
 - (b) a pharmaceutically acceptable carrier.

76909-152(S)

7. A pharmaceutical composition comprising:
- (a) type IV collagen NC1 α 3 chain monomer at a dosage of between 0.01 μ g/kg body weight and 10 mg/kg body weight; and
 - (b) a pharmaceutically acceptable carrier.
- 5 8. A pharmaceutical composition comprising:
- (a) type IV collagen NC1 α 6 chain; and
 - (b) a pharmaceutically acceptable carrier.
9. The pharmaceutical composition of claim 6 or 8, wherein the type IV collagen NC1 monomer is present in an
10 amount effective to inhibit angiogenesis.
10. The pharmaceutical composition of any one of claims 6, 8 and 9, wherein the type IV collagen NC1 monomer is present at a dosage of between 0.01 μ g/kg body weight and 10 mg/kg body weight.
- 15 11. The pharmaceutical composition of any one of claims 6 to 10, wherein the type IV collagen NC1 monomer is present at a dosage of between 0.05 μ g/kg body weight and 5 mg/kg body weight.
12. A use of the pharmaceutical composition of any one
20 of claims 6 to 8 for inhibiting tumor metastasis.
13. A use of the pharmaceutical composition of claim 6 or 8 for inhibiting tumor growth.
14. A use of the pharmaceutical composition of any one of claims 6 to 11 for treating an angiogenesis-mediated
25 disease or condition in a mammal.

76909-152 (S)

15. The use of claim 14, wherein the angiogenesis-mediated disease or condition is selected from the group consisting of solid and blood-borne tumors, diabetic retinopathy, rheumatoid arthritis, retinal
- 5 neovascularization, choroidal neovascularization, macular degeneration, corneal neovascularization, retinopathy of prematurity, corneal graft rejection, neovascular glaucoma, retrolental fibroplasia, epidemic keratoconjunctivitis, Vitamin A deficiency, contact-lens overwear, atopic
- 10 keratitis, superior limbic keratitis, pterygium keratitis sicca, sogrens, acne rosacea, phlyctenulosis, syphilis, Mycobacteria infections, lipid degeneration, chemical burns, bacterial ulcers, fungal ulcers, Herpes simplex infections, Herpes zoster infections, protozoan infections, Kaposi's
- 15 sarcoma, Mooren ulcer, Terrien's marginal degeneration, marginal keratolysis, traum, systemic lupus, polyarteritis, Wegeners sarcoidosis, scleritis, Steven's Johnson disease, radial keratotomy, sickle cell anemia, sarcoid, pseudoxanthoma elasticum, Pagets disease, vein occlusion,
- 20 artery occlusion, carotid obstructive disease, chronic uveitis, chronic vitritis, Lyme's disease, Eales disease, Bechets disease, myopia, optic pits, Stargarts disease, pars planitis, chronic retinal detachment, hyperviscosity syndromes, toxoplasmosis, post-laser complications, abnormal
- 25 proliferation of fibrovascular tissue, hemangiomas, Osler-Weber-Rendu, acquired immune deficiency syndrome, ocular neovascular disease, osteoarthritis, chronic inflammation, Crohn's disease, ulcerative colitis, psoriasis, atherosclerosis, and pemphigoid.
- 30 16. A use of the pharmaceutical composition of any one of claims 6 and 8 to 11 for the preparation of a medicament for inhibiting endothelial cell interaction with the extracellular matrix in an animal tissue or tumor.

76909-152(S)

17. A commercial package comprising an effective amount of the pharmaceutical composition according to any one of claims 6 to 11 together with instructions for the use thereof for inhibiting tumor metastasis.

5 18. A commercial package comprising an effective amount of the pharmaceutical composition according to any one of claims 6 and 8 to 11 together with instructions for the use thereof for inhibiting tumor growth.

19. A commercial package comprising an effective
10 amount of the pharmaceutical composition according to any one of claims 6 to 11 together with instruction for treating an angiogenesis-mediated disease or condition in a mammal.

20. The commercial package of claim 19, wherein the
angiogenesis-mediated disease or condition is selected from
15 the group consisting of solid and blood-borne tumors, diabetic retinopathy, rheumatoid arthritis, retinal neovascularization, choroidal neovascularization, macular degeneration, corneal neovascularization, retinopathy of prematurity, corneal graft rejection, neovascular glaucoma,
20 retrolental fibroplasia, epidemic keratoconjunctivitis Vitamin A deficiency, contact lens overwear, atopic keratitis, superior limbic keratitis, pterygium keratitis sicca, sogrens, acne rosacea, phlyectenulosis, syphilis, Mycobacteria infections, lipid degeneration, chemical burns,
25 bacterial ulcers, fungal ulcers, Herpes simplex infections, Herpes zoster infections, protozoan infections, Kaposi's sarcoma, Mooren ulcer, Terrien's marginal degeneration, marginal keratolysis, traum, systemic lupus, polyarteritis, Wegeners sarcoidosis, scleritis, Steven's Johnson disease,
30 radial keratotomy, sickle cell anemia, sarcoid, pseudoxanthoma elasticum, Pagets disease, vein occlusion,

76909-152(S)

artery occlusion, carotid obstructive disease, chronic
uveitis, chronic vitritis, Lyme's disease, Eales disease,
Bechets disease, myopia, optic pits, Stargarts disease, pars
planitis, chronic retinal detachment, hyperviscosity
5 syndromes, toxoplasmosis, post-laser complications, abnormal
proliferation of fibrovascular tissue, hemangiomas, Osler-
Weber-Rendu, acquired immune deficiency syndrome, ocular
neovascular disease, osteoarthritis, chronic inflammation,
Crohn's disease, ulcerative colitis, psoriasis,
10 atherosclerosis, and pemphigoid.

SMART & BIGGAR

OTTAWA, CANADA

PATENT AGENTS

1/28




FIG. 1

2/28




FIG. 2

3/28




FIG. 3

UNSCANNABLE ITEM

RECEIVED WITH THIS APPLICATION

(ITEM ON THE 10TH FLOOR ZONE 5 IN THE FILE PREPARATION SECTION)

DOCUMENT REÇU AVEC CETTE DEMANDE

NE POUVANT ÊTRE BALAYÉ

(DOCUMENT AU 10 IÈME ÉTAGE AIRE 5 DANS LA SECTION DE LA
PRÉPARATION DES DOSSIERS)

5/28




FIG. 5

6/28




FIG. 6

7/28




FIG. 7

8/28




FIG. 8

9/28




FIG. 9

10/28




FIG. 10

11/28




FIG. 11

12/28




FIG. 12

13/28




FIG. 13

14/28




FIG. 14

15/28




FIG. 15

16/28




FIG. 16

WO 99/49885

PCT/US99/06445

A. $\alpha 1$ (IV) NC1

17/28

```
900      910      920      930      940      950
|         |         |         |         |         |
CTGCCGCCTGCCTGCCACTGAGGGTTCCCAGCACCATGAGGGCCTGGATCTTCTTT
                                     M R A W I F F

960      970      980      990      1000     1010
|         |         |         |         |         |
CTCCTTTGCCTGGCCGGGAGGGCTCTGGCAGCCCCACTAGCCGACTACAAGGACGACGAT
L L C L A G R A L A A P L A D Y K D D D

1020     1030     1040     1050     1060     1070
|         |         |         |         |         |
GACAAGCTAGCATCTGTTGATCACGGCTTCCTTGTGACCAGGCATAGTCAAACAATAGAT
D K L A S V D H G F L V T R H S Q T I D

1080     1090     1100     1110     1120     1130
|         |         |         |         |         |
GACCCACAGTGTCTTCTGGGACCAAAATTCTTTACCACGGGTACTCTTTGCTCTACGTG
D P Q C P S G T K I L Y H G Y S L L Y V

1140     1150     1160     1170     1180     1190
|         |         |         |         |         |
CAAGGCAATGAACGGGCCCATGGCCAGGACTTGGGCACGGCCGGCAGCTGCCTGCGCAAG
Q G N E R A H G Q D L G T A G S C L R K

1200     1210     1220     1230     1240     1250
|         |         |         |         |         |
TTCAGCACAATGCCCTTCCTGTTCTGCAATATTAACAACGTGTGCAACTTTGCATCACGA
F S T M P F L F C N I N N V C N F A S R

1260     1270     1280     1290     1300     1310
|         |         |         |         |         |
AATGACTACTCGTACTGGCTGTCCACCCCTGAGCCCATGCCCATGTCAATGGCACCCATC
N D Y S Y W L S T P E P M P M S M A P I

1320     1330     1340     1350     1360     1370
|         |         |         |         |         |
ACGGGGGAAAACATAAGACCATTATTAGTAGGTGTGCTGTGTGTGAGGCGCCTGCCATG
T G E N I R P F I S R C A V C E A P A M

1380     1390     1400     1410     1420     1430
|         |         |         |         |         |
GTGATGGCCGTGCACAGCCAGACCATTTCAGATCCCACCGTGCCCCAGCGGGTGGTCCTCG
V M A V H S Q T I Q I P P C P S G W S S

1440     1450     1460     1470     1480     1490
|         |         |         |         |         |
CTGTGGATCGGCTACTCTTTTGTGATGCACACCAGCGCTGGTGCAGAAGGCTCTGGCCAA
L W I G Y S F V M H T S A G A E G S G Q

1500     1510     1520     1530     1540     1550
|         |         |         |         |         |
GCCCTGGCGTCCCCCGGCTCCTGCCTGGAGGAGTTTAGAAGTGCGCCATTCATCGAGTGT
```

FIG. 17a

WO 99/49885

PCT/US99/06445

18/28

A L A S P G S C L E E F R S A P F I E C

1560 1570 1580 1590 1600 1610
| | | | |
CACGGCCGTGGGACCTGCAATTACTACGCAAACGCTTACAGCTTTTGGCTCGCCACCATA
H G R G T C N Y Y A N A Y S F W L A T I

1620 1630 1640 1650 1660 1670
| | | | |
GAGAGGAGCGAGATGTTCAAGAAGCCTACGCCGTCCACCTTGAAGGCAGGGGAGCTGCGC
E R S E M F K K P T P S T L K A G E L R

1680 1690 1700 1710 1720 1730
| | | | |
ACGCACGTCAGCCGCTGCCAAGTCTGTATGAGAAGAACATAATGAAGCCTGACTCAGCTA
T H V S R C Q V C M R R T - -

1740 1750 1760 1770 1780 1790
| | | | |
CCGCGGGCCCTATTCTATAGTGTACCTAAATGCTAGAGCTCGCTGATCAGCCTCGACTG

FIG. 17a

WO 99/49885

PCT/US99/06445

19/28

B. $\alpha 2$ (IV) NC1

900 910 920 930 940 950
| | | | |
CTGCCGCCTGCCTGCCACTGAGGGTTCACAGCACCATGAGGGCCTGGATCTTCTTT
M R A W I F F

960 970 980 990 1000 1010
| | | | |
CTCCTTTGCCTGGCCGGGAGGGCTCTGGCAGCCCCACTAGCCGACTACAAGGACGACGAT
L L C L A G R A L A A P L A D Y K D D D

1020 1030 1040 1050 1060 1070
| | | | |
GACAAGCTAGCCGTCAGCATCGGCTACCTCCTGGTGAAGCACAGCCAGACGGACCAGGAG
D K L A V S I G Y L L V K H S Q T D Q E

1080 1090 1100 1110 1120 1130
| | | | |
CCCATGTGCCCGGTGGGCATGAACAACTCTGGAGTGGATACAGCCTGCTGTACTTCGAG
P M C P V G M N K L W S G Y S L L Y F E

1140 1150 1160 1170 1180 1190
| | | | |
GGCCAGGAGAAGGCGCACAAACCAGGACCTGGGGCTGGCGGGCTCCTGCCTGGCGCGGTTC
G Q E K A H N Q D L G L A G S C L A R F

1200 1210 1220 1230 1240 1250
| | | | |
AGCACCATGCCCTTCCTGTACTGCAACCCTGGTGATGTCTGCTACTATGCCAGCCGGAAC
S T M P F L Y C N P G D V C Y Y A S R N

1260 1270 1280 1290 1300 1310
| | | | |
GACAAGTCCTACTGGCTCTCTACCACTGCGCCGCTGCCCATGATGCCCCTGGCCGAGGAC
D K S Y W L S T T A P L P M M P V A E D

1320 1330 1340 1350 1360 1370
| | | | |
GAGATCAAGCCCTACATCAGCCGCTGTTCTGTGTGTGAGGCCCGGCCATCGCCATCGCG
E I K P Y I S R C S V C E A P A I A I A

1380 1390 1400 1410 1420 1430
| | | | |
GTCCACAGTCAGGATGTCTCCATCCCACACTGCCCAGCTGGGTGGCGGAGTTTGTGGATC
V H S Q D V S I P H C P A G W R S L W I

1440 1450 1460 1470 1480 1490
| | | | |
GGATATTCCTTCCTCATGCACACGGCGGCGGGAGACGAAGGCGGTGGCCAATCACTGGTG
G Y S F L M H T A A G D E G G G Q S L V

1500 1510 1520 1530 1540 1550

FIG. 17b

SUBSTITUTE SHEET (RULE 26)

WO 99/49885

PCT/US99/06445

20/28

| | | | |

TCACCGGGCAGCTGTCTAGAGGACTTCCGCGCCACACCATTTCATCGAATGCAATGGAGGC
S P G S C L E D F R A T P F I E C N G G

1560 1570 1580 1590 1600 1610

| | | | | |

CGCGGCACCTGCCACTACTACGCCAACAAAGTACAGCTTCTGGCTGACCACCATTCCCGAG
R G T C H Y Y A N K Y S F W L T T I P E

1620 1630 1640 1650 1660 1670

| | | | | |

CAGAGCTTCCAGGGCTCGCCCTCCGCCGACACGCTCAAGGCCGGCCTCATCCGCACACAC
Q S F Q G S P S A D T L K A G L I R T H

1680 1690 1700 1710 1720 1730

| | | | | |

ATCAGCCGCTGCCAGGTGTGCATGAAGAACCTGT**GAG**CCGGCGCGTGCCAGGGCCCCTATT
I S R C Q V C M K N L -

1740 1750 1760 1770 1780 1790

| | | | | |

CTATAGTGTCACCTAAATGCTAGAGCTCGCTGATCAGCCTCGACTGTGCCTTCTAGTTGC

FIG. 17b

WO 99/49885

PCT/US99/06445

21/28

C. $\alpha 3$ (IV)NC1

900 910 920 930 940 950
| | | | | |
CTGCCGCCTGCCTGCCACTGAGGGTTCACAGCACCATGAGGGCCTGGATCTTCTTT
M R A W I F F

960 970 980 990 1000 1010
| | | | | |
CTCCTTTGCCTGGCCGGGAGGGCTCTGGCAGCCCCGCTAGCCGACTACAAGGACGACGAT
L L C L A G R A L A A P L A D Y K D D D

1020 1030 1040 1050 1060 1070
| | | | | |
GACAAACGTGGAGACAGTGGATCACCTGCAACCTGGACAACGAGAGGCTTTGTCTTCACC
D K R G D S G S P A T W T T R G F V F T

1080 1090 1100 1110 1120 1130
| | | | | |
CGACACAGTCAAACACAGCAATTCCTTCATGTCCAGAGGGGACAGTGCCACTCTACAGT
R H S Q T T A I P S C P E G T V P L Y S

1140 1150 1160 1170 1180 1190
| | | | | |
GGGTTTTCTTTTCTTTTGTACAAGGAAATCAACGAGCCACGGACAAGACCTTGGAAC
G F S F L F V Q G N Q R A H G Q D L G T

1200 1210 1220 1230 1240 1250
| | | | | |
CTTGGCAGCTGCCTGCAGCGATTTACCACAATGCCATTCTTATTCTGCAATGTCAATGAT
L G S C L Q R F T T M P F L F C N V N D

1260 1270 1280 1290 1300 1310
| | | | | |
GTATGTAATTTTGCATCTCGAAATGATTATTCATACTGGCTGTCAACACCAGCTCTGATG
V C N F A S R N D Y S Y W L S T P A L M

1320 1330 1340 1350 1360 1370
| | | | | |
CCAATGAACATGGCTCCCATTAAGTGGCAGAGCCCTTGAGCCTTATATAAGCAGATGCACT
P M N M A P I T G R A L E P Y I S R C T

1380 1390 1400 1410 1420 1430
| | | | | |
GTTTGTGAAGGTCCTGCGATCGCCATAGCCGTTACAGCCAAACCACTGACATTCCTCCA
V C E G P A I A I A V H S Q T T D I P P

1440 1450 1460 1470 1480 1490
| | | | | |
TGTCTCACGGCTGGATTTCTCTCTGGAAAGGATTTTCATTCATCATGTTCAAGTGCA
C P H G W I S L W K G F S F I M F T S A

1500 1510 1520 1530 1540 1550

FIG. 17c

SUBSTITUTE SHEET (RULE 26)

WO 99/49885

PCT/US99/06445

22/28

GGTTCTGAGGGCGCCGGGCAAGCACTGGCCTCCCCCGGCTCCTGCCTGGAAGAATTCCGA
G S E G A G Q A L A S P G S C L E E F R

1560 1570 1580 1590 1600 1610
GCCAGCCCATTTCTAGAATGTCATGGAAGAGGAACGTGCAACTACTATTCAAATTCCTAC
A S P F L E C H G R G T C N Y Y S N S Y

1620 1630 1640 1650 1660 1670
AGTTTCTGGCTGGCTTCATTAAACCCAGAAAGAATGTTTCAGAAAGCCTATTCCATCAACT
S F W L A S L N P E R M F R K P I P S T

1680 1690 1700 1710 1720 1730
GTGAAAGCTGGGGAATTAGAAAAAATAATAAGTCGCTGTCAGGTGTGCATGAAGAAAAGA
V K A G E L E K I I S R C Q V C M K K R

1740 1750 1760 1770 1780 1790
CACTGAGGGCCCTATTCTATAGTGTACCTAAATGCTAGAGCTCGCTGATCAGCCTCGAC
H -

FIG. 17c

SUBSTITUTE SHEET (RULE 26)

23/28

D. $\alpha 4$ (IV) NC1

900 910 920 930 940 950
| | | | |
CTGCCGCCTGCCTGCCTGCCACTGAGGGTCCCAGCACCATGAGGGCCTGGATCTTCTTT
M R A W I F F

960 970 980 990 1000 1010
| | | | |
CTCCTTTGCCTGGCCGGGAGGGCTCTGGCAGCCCCGCTAGCCGACTACAAGGACGACGAT
L L C L A G R A L A A P L A D Y K D D D

1020 1030 1040 1050 1060 1070
| | | | |
GACAAGCCTGGATACCTCGGTGGCTTCCTCCTGGTTCTCCACAGTCAGACGGACCAGGAG
D K P G Y L G G F L L V L H S Q T D Q E

1080 1090 1100 1110 1120 1130
| | | | |
CCCACCTGCCCCCTGGGCATGCCCAGGCTCTGGACTGGGTATAGTCTGTTATACCTGGAA
P T C P L G M P R L W T G Y S L L Y L E

1140 1150 1160 1170 1180 1190
| | | | |
GGGCAAGAGAAAGCTCACAATCAAGACCTTGGTCTGGCAGGGTCTTGCCTTCCCGTATTT
G Q E K A H N Q D L G L A G S C L P V F

1200 1210 1220 1230 1240 1250
| | | | |
AGCACGCTGCCCTTTGCCTACTGCAACATCCACCAGGTGTGCCACTATGCCCAGAGAAAC
S T L P F A Y C N I H Q V C H Y A Q R N

1260 1270 1280 1290 1300 1310
| | | | |
GACAGATCCTACTGGCTGGCCAGCGCTGCGCCCCCTCCCCATGATGCCACTCTCTGAAGAG
D R S Y W L A S A A P L P M M P L S E E

1320 1330 1340 1350 1360 1370
| | | | |
GCGATCCGCCCCCTATGTCAGCCGCTGTGCGGTATGCGAGGCCCGGCCAGGCGGTGGCG
A I R P Y V S R C A V C E A P A Q A V A

1380 1390 1400 1410 1420 1430
| | | | |
GTGCACAGCCAGGACCAGTCCATCCCCCATGTCCGCAGACCTGGAGGAGCCTCTGGATC
V H S Q D Q S I P P C P Q T W R S L W I

1440 1450 1460 1470 1480 1490
| | | | |
GGGTATTCATTCTGATGCACACAGGAGCTGGGGACCAAGGAGGAGGGCAGGCCCTTATG
G Y S F L M H T G A G D Q G G G Q A L M

1500 1510 1520 1530 1540 1550

FIG. 17d

24/28

TCACCTGGCAGCTGCCTGGAAGATTTTCAGAGCAGCACCATTTCCTTGAATGCCAGGGCCGG
S P G S C L E D F R A A P F L E C Q G R

1560 1570 1580 1590 1600 1610
CAGGGAACCTTGCCACTTTTTTCGCAAATAAGTATAGCTTCTGGCTCACAACGGTGAAAGCA
Q G T C H F F A N K Y S F W L T T V K A

1620 1630 1640 1650 1660 1670
GACTTGCAGTTTTTCCTCTGCTCCAGCACCAGACACCTTAAAAGAAAGCCAGGCCCAACGC
D L Q F S S A P A P D T L K E S Q A Q R

1680 1690 1700 1710 1720 1730
CAGAAAATCAGCCGGTGCCAGGTCTGCGTGAAGTATAGCTAGGGGCCCTATTCTATAGTG
Q K I S R C Q V C V K Y S -

1740 1750 1760 1770 1780 1790
TCACCTAAATGCTAGAGCTCGCTGATCAGCCTCGACTGTGCCTTCTAGTTGCCAGCCATC

FIG. 17d

WO 99/49885

PCT/US99/06445

25/28

E. $\alpha 5$ (IV) NC1

900 910 920 930 940 950
| | | | |
CTGCCGCCTGCCTGCCACTGAGGGTTCCCAGCACCATGAGGGCCTGGATCTTCTTT
M R A W I F F

960 970 980 990 1000 1010
| | | | |
CTCCTTTGCCTGGCCGGGAGGGCTCTGGCAGCCCCGCTAGCTGACTACAAGGACGACGAT
L L C L A G R A L A A P L A D Y K D D D

1020 1030 1040 1050 1060 1070
| | | | |
GACAAAGGTCCCCCTGGAACCTCCTCTGTTGCACATGGATTTCTTATTACACGCCACAGC
D K G P P G T S S V A H G F L I T R H S

1080 1090 1100 1110 1120 1130
| | | | |
CAGACAACGGATGCACCACAATGCCACAGGGAACACTTCAGGTCTATGAAGGCTTTTCT
Q T T D A P Q C P Q G T L Q V Y E G F S

1140 1150 1160 1170 1180 1190
| | | | |
CTCCTGTATGTACAAGGAAATAAAAGAGCCCACGGTCAAGACTTGGGGACGGCTGGCAGC
L L Y V Q G N K R A H G Q D L G T A G S

1200 1210 1220 1230 1240 1250
| | | | |
TGCCTTCGTCGCTTTAGTACCATGCCTTTCATGTTCTGCAACATCAATAATGTTTGCAAC
C L R R F S T M P F M F C N I N N V C N

1260 1270 1280 1290 1300 1310
| | | | |
TTTGCTTCAAGAAATGACTATTCTTACTGGCTCTCTACCCCAGAGCCCATGCCAATGAGC
F A S R N D Y S Y W L S T P E P M P M S

1320 1330 1340 1350 1360 1370
| | | | |
ATGCAACCCCTAAAGGGCCAGAGCATCCAGCCATTCAATTAGTCGATGTGCAGTATGTGAA
M Q P L K G Q S I Q P F I S R C A V C E

1380 1390 1400 1410 1420 1430
| | | | |
GCTCCAGCTGTGGTGATCGCAGTTCACAGTCAGACGATCCAGATTCCCCATTGTCCTCAG
A P A V V I A V H S Q T I Q I P H C P Q

1440 1450 1460 1470 1480 1490
| | | | |
GGATGGGATTCTCTGTGGATTGGTTATTCCTTCATGATGCATAACAAGTGCAGGGGCAGAA
G W D S L W I G Y S F M M H T S A G A E

1500 1510 1520 1530 1540 1550

FIG. 17e

SUBSTITUTE SHEET (RULE 26)

26/28

| | | | |
 GGCTCAGGTCAAGCCCTAGCCTCCCCTGGTTCCTGCTTGGGAAGAGTTTCGTTTCAGCTCCC
 G S G Q A L A S P G S C L E E F R S A P
 1560 1570 1580 1590 1600 1610
 | | | | |
 TTCATCGAATGTCATGGGAGGGGTACCTGTAACTACTATGCCAACTCCTACAGCTTTTGG
 F I E C H G R G T C N Y Y A N S Y S F W
 1620 1630 1640 1650 1660 1670
 | | | | |
 CTGGCAACTGTAGATGTGTTCAGTAAACCTCAGTCAGAAACGCTGAAAGCA
 L A T V D V S D M F S K P Q S E T L K A
 1680 1690 1700 1710 1720 1730
 | | | | |
 GGAGACTTGAGGACACGAATTAGCCGATGTCAAGTGTGCATGAAGAGGACATAACGCGGC
 G D L R T R I S R C Q V C M K R T -
 1740 1750 1760 1770 1780 1790
 | | | | |
 CGCTCGAGCATGCATCTAGAGGGCCCTATTCTATAGTGTACCTAAATGCTAGAGCTCGC

FIG. 17e

27/28

F. $\alpha 6$ (IV) NC1

900	910	920	930	940	950
CTGCCGCCTGCCTGCCACTGAGGGTTCCCAGCACCATGAGGGCCTGGATCTTCTTT					
				M R A W I F F	
960	970	980	990	1000	1010
CTCCTTTGCCTGGCCGGGAGGGCTCTGGCAGCCCCACTAGCCGACTACAAGGACGACGAT					
L L C L A G R A L A A P L A D Y K D D D					
1020	1030	1040	1050	1060	1070
GACAAGCTAGCGAGCATGAGAGTGGGCTACACGTTGGTAAAGCACAGCCAGTCGGAACAG					
D K L A S M R V G Y T L V K H S Q S E Q					
1080	1090	1100	1110	1120	1130
GTGCCCCCGTGTCCCATCGGGATGAGCCAGCTGTGGGTGGGGTACAGCTTACTGTTTGTG					
V P P C P I G M S Q L W V G Y S L L F V					
1140	1150	1160	1170	1180	1190
GAGGGGCAAGAGAAAGCCCACAACCAGGACCTGGGCTTTGCTGGCTCCTGTCTGCCCCGC					
E G Q E K A H N Q D L G F A G S C L P R					
1200	1210	1220	1230	1240	1250
TTCAGCACCATGCCCTTCATCTACTGCAACATCAACGAGGTGTGCCACTATGCCAGGCGC					
F S T M P F I Y C N I N E V C H Y A R R					
1260	1270	1280	1290	1300	1310
AATGATAAATCTTACTGGCTCTCCACTACCGCCCCTATCCCCATGATGCCCGTCAGCCAG					
N D K S Y W L S T T A P I P M M P V S Q					
1320	1330	1340	1350	1360	1370
ACCCAGATTCCCCAGTACATCAGCCGCTGCTCTGTGTGTGAGGCACCCTCGCAAGCCATT					
T Q I P Q Y I S R C S V C E A P S Q A I					
1380	1390	1400	1410	1420	1430
GCTGTGCACAGCCAGGACATCACCATCCCGCAGTGCCCCCTGGGCTGGCGCAGCCTCTGG					
A V H S Q D I T I P Q C P L G W R S L W					
1440	1450	1460	1470	1480	1490
ATTGGGTACTCTTTCCTCATGCACACTGCCGCTGGTGCCGAGGGTGGAGGCCAGTCCCTG					
I G Y S F L M H T A A G A E G G G Q S L					
1500	1510	1520	1530	1540	1550

FIG. 17f

28/28

[illegible]

FIG. 17f